Howard Capital Management Inc. Invests $221,000 in BioNTech SE Sponsored ADR $BNTX

Howard Capital Management Inc. acquired a new position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 2,079 shares of the company’s stock, valued at approximately $221,000.

A number of other hedge funds have also recently made changes to their positions in BNTX. Bank of New York Mellon Corp boosted its stake in shares of BioNTech by 18,892.9% in the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company’s stock worth $63,593,000 after acquiring an additional 694,691 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of BioNTech by 94.6% in the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company’s stock worth $108,859,000 after acquiring an additional 581,173 shares during the period. Invesco Ltd. boosted its stake in shares of BioNTech by 643.7% in the first quarter. Invesco Ltd. now owns 645,142 shares of the company’s stock worth $58,747,000 after acquiring an additional 558,389 shares during the period. Millennium Management LLC increased its holdings in BioNTech by 252.5% in the 1st quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock valued at $49,625,000 after acquiring an additional 390,360 shares during the last quarter. Finally, Aberdeen Group plc increased its holdings in BioNTech by 87.2% in the 2nd quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock valued at $76,864,000 after acquiring an additional 336,260 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

BNTX has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Tuesday, October 14th. JPMorgan Chase & Co. dropped their price target on BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research note on Thursday, October 23rd. Wells Fargo & Company set a $150.00 price target on BioNTech and gave the company an “overweight” rating in a research note on Tuesday, August 5th. Morgan Stanley dropped their price target on BioNTech from $133.00 to $131.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Finally, Bank of America dropped their price target on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a research note on Wednesday, October 22nd. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $133.96.

BioNTech Price Performance

Shares of BioNTech stock opened at $104.67 on Friday. The firm has a market cap of $23.57 billion, a PE ratio of -65.42 and a beta of 1.45. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $129.27. The stock has a 50 day moving average of $102.66 and a 200 day moving average of $104.87. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The company had revenue of $306.46 million during the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. BioNTech’s revenue for the quarter was up 102.6% on a year-over-year basis. During the same period in the previous year, the business earned ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. On average, research analysts expect that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.